Gülker H, Ketteler T
Med. Klinik B, Klinikum Barmen, Wuppertal.
Z Kardiol. 1989;78 Suppl 5:49-54.
Calcium antagonists such as verapamil/diltiazem predominantly delay av-nodal conduction. Thus, the most important clinical indications for their application are the av-nodal-reentrant-tachycardia as well as the slowing of rapid ventricular response in intraatrial tachyarrhythmias. To reestablish sinus rhythm in atrial fibrillation, verapamil should be combined with chinidin. Usually, ventricular arrhythmias cannot be suppressed by calcium antagonists, but they may be indicated in exercise-induced ventricular arrhythmias and tachycardias arising from the right ventricular outflow tract. Verapamil/diltiazem are effective in ischemia-induced tachyarrhythmias, especially ventricular fibrillation, because of the reduction of ischemia-related conduction delay in the ischemic zone. The effectiveness of calcium antagonists in the secondary prevention of myocardial infarction can not yet be definitively defined.
维拉帕米/地尔硫䓬等钙拮抗剂主要延迟房室结传导。因此,其应用的最重要临床指征是房室结折返性心动过速以及房性快速心律失常时心室反应的减慢。为使心房颤动恢复窦性心律,维拉帕米应与奎尼丁联合使用。通常,钙拮抗剂不能抑制室性心律失常,但可用于运动诱发的室性心律失常以及源于右心室流出道的心动过速。维拉帕米/地尔硫䓬对缺血诱发的快速心律失常有效,尤其是心室颤动,因为它们可减少缺血区与缺血相关的传导延迟。钙拮抗剂在心肌梗死二级预防中的有效性尚未明确界定。